In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

CSL Limited is one of the world’s leading companies specializing in blood plasma therapies, nephrology, and vaccines. The ...

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

Find all the latest Q3 results 2025 updates for Hindalco, Titagarh Rail Systems, Coffee Day, Godfrey Phillips, Manappuram ...

Find all the latest Q3 results 2025 updates for TVS Srichakra, Rail Vikas Nigam, Shriram Properties, Ashok Leyland, Saint ...

ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market ...

Inc saw its stock surge 7.25% after reporting fourth-quarter earnings that significantly exceeded analyst expectations. The satellite communications company posted adjusted earnings per share of $0.32 ...

Britain is making a case to the U.S. government for its steel and aluminium products to be exempt from tariffs. The argument is based on the vital role these goods play in the U.S. defense sector and ...

The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...